|
|
Line 1: |
Line 1: |
| =Snus= | | ='''Snus'''= |
|
| |
|
| “Use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden compared with the rest of Europe [where snus is, inexplicably, banned].” | | ===2019: [https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0335-1 Snus: a compelling harm reduction alternative to cigarettes]=== |
| https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0335-1
| | *“Use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden compared with the rest of Europe [where snus is, inexplicably, banned].” |
| | *Citation: Clarke, E., Thompson, K., Weaver, S. et al. Snus: a compelling harm reduction alternative to cigarettes. Harm Reduct J 16, 62 (2019). doi:10.1186/s12954-019-0335-1 |
| | *Acknowledgement: The review was funded by Imperial Brands Plc. |
| | <br> |
|
| |
|
| =HnB / HTP= | | =HnB / HTP= |